Table 1. Summary of In Vivo Antitumor Efficacy by 5DEX-0509R Treatment.
| cancer types | mouse strain | cell line | CR (%) | TGI (%) |
|---|---|---|---|---|
| colon | Balb | Colon26 | 100 | 100 |
| colon | Balb | CT26 | 83.3 | 96.3 |
| osteosarcoma | Balb | K7M2 | 60 | 94.5 |
| bladder | B6C3HF1 | MBT2 | 37.5 | 93.9 |
| breast | Balb | EMT6 | 60 | 93 |
| colon | B6 | MC38 | 50 | 89 |
| B cell | Balb | A20 | 60 | 85.3 |
| pancreatic | B6 | Pan02 | 0 | 81.1 |
| liver | B6 | Hepa1–6 | 40 | 70.4 |
| kidney | Balb | Renca | 0 | 67.7 |
| HNSCC | C3H | SCCVII | 0 | 67.2 |
| prostate | B6 | RM-1 | 0 | 63.9 |
| lung | B6 | LLC | 0 | 63.3 |
| ovary | B6C3HF1 | HM-1 | 0 | 55.8 |
| AML | SCID/Beige | MV4;11 | 0 | 51.7 |
| T cell lymphoma | Balb | EG7 | 0 | 46.8 |
| melanoma | B6 | B16_BL6 | 0 | 40.9 |